论文部分内容阅读
目的研究肿瘤坏死因子相关的凋亡诱导配体(TRAIL)联合长春新碱(VCR)诱导急性早幼粒白血病细胞株HL-60细胞凋亡,探讨其应用于临床的可行性。方法在对数生长期的HL-60细胞中分别加入不同浓度的TRAIL和0.1mg/L的VCR,采用MTT比色法测定TRAIL和VCR单独和联合应用时对细胞的生长抑制率,并用流式细胞术检测细胞凋亡。结果TRAIL联合VCR可协同降低HL-60细胞活力,抑制细胞增殖,诱导细胞凋亡。且24h内当TRAIL浓度<100g/L时促调亡作用随TRAIL浓度增加及培养时间延长而增强(P<0.05),而24h内当TRAIL浓度≥100μg/L时以及24h后虽抑制率和调亡率较高,但随浓度增高作用无显著差别(P>0.05)。结论TRAIL与VCR具有协同作用,能高效杀灭白血病细胞。TRAIL是一种有望应用于白血病临床治疗的新型生物制剂。
Objective To investigate the apoptosis of acute promyelocytic leukemia HL-60 cells induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) combined with vincristine (VCR) and to explore its feasibility in clinical application. Methods Different concentrations of TRAIL and 0.1 mg / L VCR were added to HL-60 cells in logarithmic growth phase. The growth inhibition rates of TRAIL and VCR alone and in combination were determined by MTT assay. Cytometry detects apoptosis. Results TRAIL combined with VCR can synergistically reduce the viability of HL-60 cells, inhibit cell proliferation and induce apoptosis. In 24 hours, when the concentration of TRAIL was less than 100g / L, the pro-apoptotic effect was enhanced with the increase of TRAIL concentration and culture time (P <0.05) Mortality higher, but with no significant difference in concentration (P> 0.05). Conclusion TRAIL and VCR have a synergistic effect and can effectively kill leukemia cells. TRAIL is a promising new biological agent for the clinical treatment of leukemia.